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Abstract. Background/Aim: This study sought to determine
whether an autoimmune background could identify patients
with HER2-positive early breast cancer (EBC) who derive
differential benefit from primary adjuvant trastuzumab-based
therapy. Patients and Methods: HERA is an international
randomized trial of 5,102 women with HER2-positive EBC,
who were enrolled to either receive adjuvant trastuzumab or
not. In this exploratory analysis, the interaction between
autoimmune history and the magnitude of trastuzumab benefit
was evaluated. Results: A total of 5,099 patients were included
in the current analysis. Among them, 325 patients (6.4%) had
autoimmune disease history, 295 of whom had active disease.
Patients were randomly assigned to trastuzumab or no-
trastuzumab groups. Similar reductions in the risk of events in
patients with and without autoimmune history were observed
(interaction p=0.95 for disease-free survival, and p=0.62 for
overall survival). Conclusion: No evidence of a differential
benefit from trastuzumab in patients with a medical history of
autoimmune disease was found.  
The ErbB2/HER2 (human epidermal growth factor receptor 2)
oncogene encoding for a member of the epidermal growth
factor family, was found to be amplified in about 20% of
breast cancer patients and is associated with a shorter time to
relapse and a lower survival rate (1, 2). Trastuzumab, a
monoclonal antibody against HER2 received approval for the
treatment of patients with HER2-positive metastatic breast
cancer on the basis of a pivotal trial (3). At the turn of the 21st
century, a number of randomized prospective clinical trials
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were launched to evaluate the role of trastuzumab given in
addition to chemotherapy in the adjuvant setting. These studies
generated highly consistent results, showing that the addition
of trastuzumab to chemotherapy decreased recurrence by
approximately 50% and mortality by 30% (4-7). 
One of these trials was the HERA (BIG 1-01) trial, which
randomized 5,102 patients who were enrolled after
completion of their postoperative chemotherapy. The final
analysis of an 11 years follow-up showed that the addition
of 1 year of adjuvant trastuzumab resulted in a constant 24%
relative reduction in the risk of a disease-free survival event
(DFS), and a 26% relative reduction in the risk of death (5).
In the last few decades the role of the immune system in the
outcome of cancer treatment has moved rapidly from preclinical
evidence to clinical practice. The innate immune system involves
activation of dendritic cells, natural killer cells, granulocytes as
well as other cells and the complement system, and is associated
with a rapid non-specific quick immune response without the
need of memory or previous exposure (8). On the other hand,
the adaptive immune response develops slowly and is mediated
by a response to a specific antigen by B cells and T cells.
Adaptive and innate immune mechanisms are essential players
in the therapeutic effects of monoclonal antibody-based anti-
HER2 therapy (9-11). Higher levels of tumor infiltrating
lymphocytes (TILs) in the primary tumor at diagnosis are
associated with increased benefit from trastuzumab (12). 
Autoimmune diseases may cause significant and chronic
morbidity, and women have a 2.7-times greater risk than men to
develop an autoimmune disease (13). In this HERA exploratory
analysis, we sought to examine whether autoimmunity
background is associated with a different outcome in patients
treated with primary trastuzumab-based therapy.
Patients and Methods
Study patients. HERA is an open-label, phase III, international
multicenter randomized trial. A detailed description of the trial, its
regimens, and key eligibility criteria are provided in the original
report (4). Briefly, between Dec 7, 2001, and June 20, 2005, 5,102
patients were recruited and randomly assigned (1:1:1) to one of the
three treatments arms: observation (without trastuzumab), adjuvant
treatment of trastuzumab for 1 year or for 2 years. 
The comparison of the trastuzumab arms versus observation was
based on the intention-to-treat (ITT) principle, after exclusion of three
patients (one from each group) because of no record of written
informed consent (Figure 1). To be eligible, participants had to have
central laboratory (Kassel, Germany) confirmation of locally assessed
HER2-positive disease and left ventricular ejection fraction (LVEF)
of at least 55% after completion of chemotherapy and radiotherapy if
applicable. History of autoimmune diseases was prospectively
collected in the clinical database and was retrieved for the sake of this
analysis. Of note, this analysis was not preplanned as a part of the
data analysis plan of the trial. The HERA trial was approved by the
ethics committees of all participating sites and this exploratory
analysis was approved by the HERA executive committee.
Statistical analysis. In the current analysis, we investigated the
potential impact of autoimmune diseases on patient’s outcome. We
hypothesized that autoimmune history of the patients may elicit
robust antitumor immune response, boosting the antitumor activity
of trastuzumab, thus prolonging survival. Therefore, the a priori
hypothesis was that patients with autoimmune disease background
would have superior long-term outcomes when treated with
trastuzumab. We evaluated the association between autoimmune
background and classic clinicopathological factors using Chi-
squared tests. Autoimmune diseases as well as other comorbidities
in the HERA database were coded using the WHO-DDE (World
Health Organization Drug Dictionary Enhanced). This analysis was
restricted to autoimmune predefined diseases for which there was
direct or indirect evidence for autoimmune pathogenesis (13). Two
survival endpoints were investigated: disease-free survival (DFS)
and overall survival (OS), which were defined in the HERA study
(4). In these exploratory analyses, the two trastuzumab treatment
arms were combined. A Cox proportional hazards regression model
was used to assess the interaction between autoimmune history and
treatment (1+2 years trastuzumab and observation). Cox modelling
was also used with the overall population and for the two
autoimmune status sub-populations to estimate unadjusted hazard
ratios (HR) and 95%CIs, comparing 1+2 years trastuzumab and
observation. 
Results
Association between autoimmune disease history and
clinicopathological characteristics. The HERA clinical
database was screened for preferred terms of predefined
autoimmune comorbidities (13), for which there was clear
direct or indirect evidence for autoimmune pathogenesis. All
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Figure 1. CONSORT diagram. Study flowchart shows the process of
patient selection.
patients who were enrolled in the HERA trial were included
in the current analysis (N=5,099), of whom 4,774 (93.6%)
patients had no history of autoimmune disease at baseline,
while 325 patients (6.4%) had autoimmune disease history
(Figure 1). 
A summary of the autoimmune diseases (preferred terms)
that were detected in the HERA database are reported in
Table I. Most of the autoimmune diseases were reported as
active at baseline (N=295, 90.7%) and the majority of them
were associated with hypothyroidism (N=219, 67.4%).
Table II lists the patients’ characteristics according to
autoimmune diseases history. There was some evidence that
patients with an autoimmune background were more likely
to be older (p<0.001) and postmenopausal (p<0.001)
(Table II).
Prognostic value of the autoimmune background in
trastuzumab treated patients. The association between
autoimmune background and DFS and OS at a median
follow-up of 11 years (IQR=10.09-11.53) was evaluated.
During this follow-up period, 1,631 patients experienced a
DFS event and 1,037 patients an OS event. One or two
years of trastuzumab treatment of patients with no
autoimmune history, compared to no trastuzumab, reduced
the risk of DFS event (Hazard Ratio (HR)=0.77, 95%
Confidence Interval (CI)=0.69-0.85) and death (0.74,
95%CI=0.65-0.84). In patients with autoimmune history
treated with trastuzumab, the estimated magnitude of
reduction in the risk of DFS or OS events was similar to
that seen in the no-immune history group (DFS HR=0.76,
95%CI=0.51-1.12; OS HR=0.65, 95%CI=0.40-1.07) (Table
III). Evaluation of the interaction between autoimmune
disease and treatment suggests that there is no evidence to
reject the null hypothesis that there is no interaction (DFS
p=0.95, OS p=0.62). 
Discussion
In the present study, we sought to determine whether an
autoimmune disease background could identify patients who
derive different benefit from primary trastuzumab-based
therapy. While there is a growing body of evidence that
shows that the immune system contributes substantially to
the therapeutic effects of trastuzumab, we were not able to
demonstrate an interaction between autoimmune disease
background and the level of benefit from trastuzumab
treatment. 
In HER2 positive breast cancer, the presence of TILs has
been shown to have a prognostic value for improved
probability of cure in early stages (14) and predictive for
trastuzumab benefit (12). These TILs may represent a basic
host anti-tumour immune response, which can be further
boosted by immunotherapeutic agents. The presence of an
autoimmune response is the defining characteristic of an
autoimmune disease. Autoimmune diseases can be initiated
by different antigens and despite their diverse etiology they
are characterized by the presence of self-reactive T
lymphocytes (15) and the loss of inhibitory pathways in the
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Table I. Summary of autoimmune disease at baseline.
                                                                                                                                                              Diagnosis
Thyroid background                         Autoimmune disease preferred term               Active (N=295)             Not active (N=30)              Total (N=325)
                                                                                                                                                                                                                                    
Hyperthyroidism                                               Hyperthyroidism                                            41                                   11                                     52
                                                                                    Total                                                     41                                   11                                     52
Hypothyroidism                                             Hypothyroidic Goitre                                          5                                     1                                       6
                                                                           Hypothyroidism                                          213                                     5                                   218
                                                                    Primary Hypothyroidism                                       1                                     0                                       1
                                                                                    Total                                                   219                                     6                                   225
Thyroiditis                                                   Autoimmune Thyroiditis                                       7                                     1                                       8
                                                                               Thyroiditis                                                   2                                     3                                       5
                                                                        Thyroiditis Chronic                                           1                                     0                                       1
                                                                                    Total                                                     10                                     4                                     14
No Thyroid Background                      Cutaneous Lupus Erythematosus                                 2                                     0                                       2
                                                                           Lupus Nephritis                                              1                                     0                                       1
                                                                          Multiple Sclerosis                                             2                                     1                                       3
                                                                         Myasthenia Gravis                                            1                                     1                                       2
                                                                       Rheumatoid Arthritis                                        12                                     6                                     18
                                                               Systemic Lupus Erythematosus                                  2                                     1                                       3
                                                                    Type 1 Diabetes Mellitus                                       4                                     0                                       4
                                                                                  Vitiligo                                                     1                                     0                                       1
                                                                                    Total                                                     25                                     9                                     34
form of clonal anergy or immunological ignorance (16). 
Our hypothesis of enhanced immune response during
trastuzumab therapy for early breast cancer in patients with
a history of autoimmune diseases is based on studies that
demonstrated that part of the trastuzumab therapeutic effect
is immune-dependent. It is possible that trastuzumab induces
antibody-dependent cellular cytotoxicity (ADCC) by
directing effector cells to kill HER2-expressing cancer cells
(17). ADCC is directed mainly by the Fc receptor, which is
present on natural killer cells that recognize the Fc portion
of trastuzumab. This results in an improved response in
subjects with a high percentage of TILs in their tumours and
an augmented capacity to mediate ADCC (18). Other
immune mechanisms involved in trastuzumab activity
include: complement-dependent cytotoxicity, phagocytosis of
monoclonal antibody-opsonised target cells through receptors
for the Fc portion of IgG, induction of production of
immunomodulatory cytokines, induction of cross-
presentation of tumour antigens and induction of cross-talk
among immune cells (9, 19-25). While these mechanisms
may enhance trastuzumab activity, trastuzumab treatment is
not associated with increased clinical manifestations of
autoimmunity (5). This may be related to the specific nature
of anti-HER2 treatment and may be also the reason why the
presence of autoimmune diseases is not associated with an
increased benefit from trastuzumab administration. Indeed,
our data suggest that autoimmune comorbidities do not
influence trastuzumab effects in the adjuvant setting. This
information might be helpful information for clinicians who
are reluctant to provide trastuzumab to patients with
autoimmune diseases. 
The strengths of this study include the analysis of a
homogenous population, which was observed prospectively
and randomized to trastuzumab adjuvant therapy and has a
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Table II. Summary of patient's demographic and breast cancer characteristics according to autoimmune background.
Characteristic                                                                                      Autoimmune history                   No autoimmune history                      p-Value
                                                                                                                      (N=325)                                        (N=4774)                                chi-square
Age at study entry (years) - no.(%)                                                                                                                                                                         
  <35                                                                                                            11 (3.4)                                          367 (7.7)                                   <0.001
  35-49                                                                                                       111 (34.2)                                      2153 (45.1)                                      
  50-59                                                                                                       130 (40.0)                                      1509 (31.6)                                      
  ≥60                                                                                                            73 (22.5)                                        745 (15.6)                                      
Previous (neo)adjuvant chemotherapy - no.(%)                                                                                                                                                      
  No anthracycline                                                                                      13 (4.0)                                          289 (6.1)                                      0.168
  Anthracycline but no taxane                                                                  217 (66.8)                                      3252 (68.1)                                      
  Anthracycline and taxane                                                                        95 (29.2)                                      1233 (25.8)                                      
Menopausal status – no.(%)                                                                                                                                                                                     
  Premenopausal                                                                                          38 (11.7)                                         679 (14.2)                                 <0.001
  Uncertain                                                                                                102 (31.4)                                      1961 (41.1)                                      
  Postmenopausal                                                                                      185 (56.9)                                      2134 (44.7)                                      
Pathological tumor size (cm) – no.(%)                                                                                                                                                                    
  0-2                                                                                                           130 (40.0)                                      1873 (39.2)                                    0.907
  2-5                                                                                                           138 (42.5)                                      2087 (43.7)                                      
  >5                                                                                                              16 (4.9)                                          257 (5.4)                                        
  Not assessed (neoadjuvant chemotherapy)                                             38 (11.7)                                         525 (11.0)                                      
Missing size                                                                                                   3 (0.9)                                            32 (0.7)                                        
Pathological nodal status – no.(%)                                                                                                                                                                           
Negative                                                                                                    103 (31.7)                                      1543 (32.3)                                    0.966
  1-3 Positive nodes                                                                                    95 (29.2)                                      1369 (28.7)                                      
  ≥4 Positive nodes                                                                                     89 (27.4)                                      1336 (28.0)                                      
  Not assessed (neoadjuvant chemotherapy)                                             38 (11.7)                                         525 (11.0)                                      
Missing                                                                                                          0 (0.0)                                              1 (0.0)                                        
Local hormone-receptor status – no.(%)                                                                                                                                                                 
  Negative                                                                                                  174 (53.5)                                      2354 (49.3)                                    0.152
  Positive                                                                                                   151 (46.5)                                      2420 (50.7)                                      
Histological grade of tumor – no.(%)                                                                                                                                                                      
  G1                                                                                                               3 (0.9)                                          103 (2.2)                                      0.084
  G2                                                                                                           104 (32.0)                                      1548 (32.4)                                      
  G3                                                                                                           210 (64.6)                                      2879 (60.3)                                      
  Not assessed                                                                                               8 (2.5)                                          243 (5.1)                                        
  Missing                                                                                                       0 (0.0)                                              1 (0.0)                                        
long follow-up period. Moreover, the clinical data and
characteristics were well annotated including the presence of
autoimmune conditions. Conversely, there are limitations that
should be taken into account. As this is not a pre-planned
analysis, it is possible that unidentified confounders were
non-randomly distributed between groups of interest.
Autoantibody (such as anti-thyroglobulin) levels were not
collected and information regarding autoimmunity was
analyzed on the basis of baseline data only, which excluded
post-treatment effects and dynamics. Another weakness of
our study is that the selected cases with autoimmune disease
history are composed mainly of patients with thyroid
diseases especially hypothyroidism of different levels of
severity which could have an influence on the end-point.
Moreover, the numbers in the autoimmune group are very
small; therefore, the test of interaction will be
correspondingly low powered. 
In conclusion, in this unplanned analysis of a prospective
trial we did not confirm the hypothesis that autoimmunity
could activate trastuzumab-directed responses triggering an
immune response, such that the benefit from trastuzumab
would be greater in such patients than those without a history
of autoimmune disease.
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